Indeed, immune modulating inhibitors against CTLA-4 (Ipilimumab) or PD-1 (Nivolumab, Pembrolizumab) and PD-L1 (Atezolizumab) have already been approved for various cancers such as melanoma, lung, kidney and bladder cancer.6-10. This evidence concerns the gene CD274 and melanoma.